Purification 2020

Achieving optimal downstream bioprocessing for AAV vector

Cell & Gene Therapy Insights 2020; 6(11), 1601–1606


Published: 23 December 2020
Eric Gershenow

Eric Gershenow is associate director for gene therapy downstream process development and manufacturing at IVERIC bio. Eric has more than 20 years of industry experience in downstream process and technology development for a wide spectrum of products with 10+ years of experience supporting protein and gene therapy applications. Most recently Eric was Associate Principal Scientist leading a group of scientists to develop downstream processes for multiple AAV serotypes to establish an internal platform and support client programs. Prior to that, Eric had spent more than 12 years at Pall Biotech with increasing responsibilities, working with customers facilitating product trials, technical seminars/ consultations, and most notably continuous process modeling to drive Pall’s continuous product portfolio that included BioSMB chromatography systems (now part of Sartorius). Eric has held different roles for various companies including Tosoh Bioscience, Human Genome Sciences, The American Red Cross (Prometic BioTherapeutics), Neose Technologies and Life Technologies, focused on purification development of fermentation, plasma and cell culture-based products. Eric holds a BS in Chemistry from Shippensburg University, PA.